文献速递白血病MDS 与骨髓增殖性肿瘤

幼年型粒单核细胞白血病患者的观察等待策略:法国队列研究结果

The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.
PubMed 文献 · Blood · 2026-01-01

该法国全国性队列纳入161例经遗传学鉴定的幼年型粒单核细胞白血病(JMML)患者,35例初始采用观察等待(W&W)策略,2016至2021年期间该策略采用率升至39%。中位随访6.5年,35例中30例(86%)获得长期生存,5年总生存率和无事件生存率分别为93.1%和84.5%。

要点

  • 观察等待(W&W)策略在35例JMML患者中实施,2016至2021年采用率达39%。
  • 中位随访6.5年,35例中30例(86%)获长期生存,5年总生存率93.1%、无事件生存率84.5%。
  • 5例疾病进展,多在诊断后2年内;克隆性造血在幸存者中持续存在(18/20)。

核心结论

  • 观察等待(W&W)策略可使部分JMML患者获得长期生存,支持其作为高达30%患者的可行替代方案,可能使其免于造血干细胞移植(HSCT)相关风险。
  • 鉴于克隆性造血持续存在及血液外并发症风险,长期监测仍然必要。

研究设计与样本

  • 真实世界研究,分析法国全国性队列中161例经遗传学鉴定的JMML患者。
  • 35例患者初始采用观察等待(W&W)策略,2016至2021年期间W&W采用率达39%。

主要发现

  • W&W组患者突变分布为CBL(43%)、NRAS(34%)或纯合胚系SH2B3(14%)。
  • 中位随访6.5年,35例中30例(86%)获得长期生存,伴骨髓增殖症状部分或完全缓解,但几乎所有幸存者克隆性造血持续存在(18/20)。
  • 5例患者(CBL,n=3;NRAS,n=1;PTPN11,n=1)发生疾病进展,多在诊断后2年内。
  • W&W队列5年总生存率为93.1%,无事件生存率为84.5%。
  • NRAS突变病例中,年龄<30个月、胎儿血红蛋白正常至轻度升高、血小板计数>45×10^9/L、无额外体细胞突变及低DNA甲基化谱与良好结局相关;CBL驱动JMML中未发现不良演变的预测因素;纯合胚系SH2B3患者中W&W均有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive pediatric myeloproliferative neoplasm for which hematopoietic stem cell transplantation (HSCT) is currently the only established curative therapy. However, a watch-and-wait (W&W) approach has shown promise for long-term survival in selected cases. In this real-world study, we analyzed outcomes of patients with JMML initially managed with a W&W strategy within a nationwide cohort of 161 genetically characterized cases. W&W was chosen for 35 patients, with increasing adoption over time, reaching 39% in the 2016-to-2021 period. Most patients carried mutations in CBL (43%), NRAS (34%), or homozygous germ line SH2B3 (14%). Over a median follow-up of 6.5 years, 30 of 35 (86%) achieved long-term survival with partial or complete resolution of myeloproliferative symptoms, although clonal hematopoiesis persisted in nearly all survivors (18/20). Disease progression occurred in 5 patients (CBL, n = 3; NRAS, n = 1; PTPN11, n = 1), mostly within 2 years after diagnosis. Overall, in the W&W cohort, the 5-year overall and event-free survivals were 93.1% and 84.5%, respectively. In NRAS-mutated cases, age of <30 months, normal to slightly elevated fetal hemoglobin, platelet counts of >45 × 109/L, the absence of additional somatic mutations, and low DNA methylation profile were associated with favorable outcomes. In CBL-driven JMML, no predictive factor of adverse evolution was identified. Notably, W&W was effective in all patients with homozygous germ line SH2B3. These findings support W&W as a viable alternative in up to 30% of patients with JMML, potentially sparing them from HSCT-associated risks. Given the persistence of clonal hematopoiesis and the risk of extrahematological complications, long-term monitoring remains essential.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Neven Q, Arfeuille C, Caye-Eude A, et al. The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort. Blood. 2026. PMID: 40971523. doi:10.1182/blood.2025029916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。